Ozmosi | BAY-1129980 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

BAY-1129980

Alternative Names: bay-1129980, bay1129980, bay 1129980
Clinical Status: Inactive
Latest Update: 2019-12-11
Latest Update Note: Clinical Trial Update

Product Description

a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer

Mechanisms of Action: LYPD3 Inhibitor

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT02134197

BAY1129980

P1

Terminated

Oncology Solid Tumor Unspecified|Oncology Hematological Unspecified

2018-08-30

36%

2019-12-12

Patient Enrollment|Primary Endpoints|Treatments|Trial Status

Recent News Events

Date

Type

Title